Get all premium features to the best stock analysis tool

JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd.

JERUSALEM, March 16, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days.

JERUSALEM, March 2, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l.

JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support.

JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd.

JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during HealthIL Week 2026.

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its financial results and corporate highlights for the nine months ended September 30, 2025.